AURA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AURA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aura Biosciences has the GF Value Rank of 0.
GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of Aura Biosciences's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Janet Jill Hopkins | officer: See Remarks | C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON MA 01235 |
De Los Pinos Elisabet | director, officer: Chief Executive Officer | C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
Julie B Feder | officer: Chief Financial Officer | C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494 |
Matrix Capital Management Company, Lp | 10 percent owner | 1000 WINTER STREET, C/O MATRIX CAPITAL MANAGEMENT, WALTHAM MA 02451 |
David Michael Johnson | director | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Cadmus Rich | officer: See Remarks | C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
Rosch Mark De | officer: Chief Operating Officer | C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
Medicxi Ventures Management (jersey) Ltd | 10 percent owner | C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG |
Medicxi Growth I Lp | 10 percent owner | C/O ELIAN FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST HELIER Y9 JE4 9WG |
Giovanni Mariggi | director | C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
Medicxi Growth I Gp Ltd | 10 percent owner | C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG |
Medicxi Growth Co-invest I Lp | 10 percent owner | C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG |
David E. Goel | 10 percent owner | C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451 |
Karan S. Takhar | director | C/O ZENTALIS PHARMACEUTICALS,INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Antony C. Mattessich | director | C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730 |
From GuruFocus
By Business Wire Business Wire • 05-12-2023
By GuruFocus News • 02-14-2025
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 05-10-2024
By Business Wire • 08-09-2023
By GuruFocus Research • 02-06-2024
By Marketwired • 11-12-2024
By Marketwired • 10-17-2024
By Marketwired • 05-30-2024
By Marketwired • 05-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.